Diligence memo · auto-generated · as of July 2, 2026
Vynca, Inc.
Vynca, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Vynca, Inc. operates in Other Health Care, based in San Mateo.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vynca, Inc. has raised $38M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2021-12-23.
Most recent recorded round closed around 2024-12-23.
Valuation (modeled)modeled
Provath models Vynca, Inc. at approximately $32M (range $13M–$51M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.21× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 55 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 4.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 90% of Other Health Care peers (5377 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.